[Questionnaire for assessing the risk of venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian antithrombotic guideline entitled "Risk reduction and treatment of venous thromboembolism"].
A large proportion of hospitalized surgical and medical patients are at risk for venous thromboembolism. Depending on the type of surgical intervention, venous thrombosis develops in 15-60% of surgical patients without prophylaxis. Although venous thromboembolism is most often considered to be associated with recent surgery or trauma, 50 to 70% of symptomatic thromboembolic events and 70 to 80% of fatal pulmonary embolisms occur in nonsurgical patients. International and national registries show that the majority of at-risk surgical patients actually received the appropriate thromboembolic prophylaxis. However, despite of international and national recommendations, prophylaxis was not provided for a large proportion of at-risk medical patients. The rate of medical patients receiving prophylaxis should be increased, and appropriate thrombosis prophylaxis should be offered to at-risk medical patients. The thrombosis risk assessment is an important tool to identify patients at increased risk for venous thromboembolism, to simplify decision making on prophylaxis administration, and to improve the adherence to guidelines. When the risk is recognized, if there is no contraindication, prophylaxis should be ordered. The 4th Hungarian Antithrombotic Guideline entitled "Risk reduction and treatment of thromboembolism" calls attention to the importance of risk assessment and for the first time it includes and recommends risk assessment models for hospitalized surgical and medical patients. The risk assessment models are presented and the evidence based data for the different risk factors included in these models are reviewed.
Dávid
Marianna
M
Pécsi Tudományegyetem, Altalános Orvostudományi Kar I. Belgyógyászati Klinika, Pécs. david-m@freemail.hu
Losonczy
Hajna
H
Udvardy
Miklós
M
Boda
Zoltán
Z
Blaskó
György
G
Tar
Attila
A
Pfliegler
György
G
D000367:Age Factors; D000925:Anticoagulants / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications; D015992:Body Mass Index; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D020022:Genetic Predisposition to Disease; D006760:Hospitalization; D006801:Humans; D006814:Hungary; D007239:Infections / Q000150:complications; D015212:Inflammatory Bowel Diseases / Q000150:complications; D008124:Locomotion; D009154:Mutation; D009369:Neoplasms / Q000150:complications; D009401:Nephrosis / Q000150:complications; D009765:Obesity / Q000150:complications; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D012042:Registries; D012131:Respiratory Insufficiency / Q000150:complications; D018570:Risk Assessment; D012307:Risk Factors; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D011795:Surveys and Questionnaires / Q000592:standards*; D014648:Varicose Veins / Q000150:complications; D014689:Venous Insufficiency / Q000150:complications; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control*
D000925:Anticoagulants; D003278:Contraceptives, Oral, Hormonal